Helicobacter Pylori Infections - Epidemiology Forecast - 2032

This ‘Helicobacter pylori Infection - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Helicobacter pylori Infection, historical and forecasted epidemiology as well as the Helicobacter pylori Infection trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Helicobacter pylori Infection Disease Understanding

Helicobacter pylori (H. pylori) is a spiral-shaped, flagellated gram-negative bacterium colonizing the human stomach. It usually infects the stomach and small intestine. It is designated as a Class I carcinogen by WHO and is a Qualifying Pathogen under the US FDA GAIN Act.

Usually acquired during childhood, it is one of the most common chronic bacterial infections globally. Most infected individuals with it remain asymptomatic for a very long duration. Patients harboring the bacteria usually have symptoms, such as abdominal pain, nausea, vomiting, and the development of dyspepsia when the disease progresses to gastritis and peptic ulcer disease. Most of these are synonymous with other gastric conditions.

It is the strongest known risk factor for non-cardia gastric adenocarcinoma and is usually associated with chronic gastritis, the development of preneoplastic lesions, or peptic ulcer disease.

The infection is usually transmitted by the fecal-oral, gastric-oral, oral-oral, or sexual routes, and its prevalence varies widely with geography. Generally, the prevalence is higher in developing and resource-poor countries than in developed countries and is usually impacted by climatic conditions, host-microbe interaction, genetics, GI microbiota, or medication.

Several studies have validated that H. pylori is also present in the dental plaque and saliva of infected individuals, and therefore the H. pylori infection spreads at a much higher rate than expected and, especially, transmission between family members is frequent.

Helicobacter pylori Infection Diagnosis

There is no single accurate diagnostic tool or method and the current diagnosis regime is usually a combination of both invasive and non-invasive methods.

The non-invasive methods, that determine eradication rates are based on the presence of bacterial enzymes, antigens, antibodies, or DNA sequences and include 13C or 14C UBT, SAT, serology, etc. While the invasive methods include endoscopy and gastric biopsy followed by RUT, histology, culture, or a PCR that are clinically significant.

UBT is regarded as a gold standard non-invasive method for H. pylori diagnosis with high sensitivity, specificity, and accuracy. It has been used for about 30 years and is still the most popular and common noninvasive test that indirectly measures the activity of bacterial urease produced by H. pylori in the stomach. The test exploits the hydrolysis of orally administered urea by H. pylori. While SAT is a direct test for initial infection and is based on the detection of H. pylori antigens in the stool.

Serology tests for H. pylori detect antibodies against H. pylori by ELISA, immunoblotting, and EIA. Although more tests for IgA, IgG, and IgM antibodies are performed, only the IgG antibody test is reliable.

Invasive tests include endoscopy and gastric biopsy followed by either RUT, histology or culture, or molecular methods on biopsy samples. Each invasive test offers a specific clinical advantage, and RUT is the quickest test that provides an opportunity to start the treatment immediately. The histological examination provides a comprehensive assessment of gastric mucosa and thus helps in short-term and long-term management strategies.

Helicobacter pylori Infection Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Helicobacter pylori Infection, Gender-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection, and Age-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection scenario of Helicobacter pylori Infection in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Helicobacter pylori Infection Detailed Epidemiology Segmentation

• In 2021, the diagnosed prevalent cases of Helicobacter pylori Infection were estimated to be 321,978,200 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.2% during the study period (2019-2032).
• Among the 7MM, the United States accounted for nearly 37% of the total diagnosed prevalent cases of Helicobacter pylori Infection in the 7MM in the year 2021 which are expected to increase further by 2032.
• Among the EU5 countries, France had the highest diagnosed prevalent cases of Helicobacter pylori Infection with 31,931,498 cases in 2021, while the United Kingdom had the lowest diagnosed prevalent population of Helicobacter pylori Infection with 23,913,563 cases in 2021.
• In 2021, the diagnosed prevalent population of Helicobacter pylori Infection in Japan was found to be 64,413,456 cases, which is expected to change for the study period of 2019-2032.
• According to estimates based on the epidemiology model for Helicobacter pylori Infection, the gender distribution of the disease suggests a male predominance across the 7MM, with 62,422,016 male and 56,837,414 female cases in the United States in 2021.
• According to estimates based on the epidemiology model for Helicobacter pylori Infection, the age-specific diagnosed prevalent cases of the disease suggests that >40 age group make the majority of the Helicobacter pylori Infection cases, followed by 20-40 age-group. While the least cases were in the 0-20 age group.
• In 2021, with 77,518,629 cases, approximately 65% of the Helicobacter pylori Infection cases were for the >40 age group, followed by 25% in 20-40 age group in the US.

Scope of the Report

• The report covers a descriptive overview of Helicobacter pylori Infection, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of Helicobacter pylori Infection.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, Diagnosed Prevalent Cases of Helicobacter pylori Infection, Gender-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection, and Age-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection.

Report Highlights

• 11-Year Forecast of Helicobacter pylori Infection
• The 7MM Coverage
• Diagnosed Prevalent Cases of Helicobacter pylori Infection
• Gender-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection
• Age-specific Diagnosed Prevalent Cases of Helicobacter pylori Infection

Key Questions Answered

• What are the disease risk and burdens of Helicobacter pylori Infection?
• What is the historical Helicobacter pylori Infection patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Helicobacter pylori Infection at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with Helicobacter pylori Infection?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Helicobacter pylori Infection during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy

The Helicobacter pylori Infection report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Helicobacter pylori Infection epidemiology forecast.
• The Helicobacter pylori Infection epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• Helicobacter pylori Infection epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032